Long-term follow-up of otherwise healthy term infants with marked hyperbilirubinaemia: should the limits of exchange transfusion be changed in Turkey?

Duman N., ÖZKAN H., Serbetcioglu B., Ogun B., Kumral A., Avci M.

ACTA PAEDIATRICA, cilt.93, sa.3, ss.361-367, 2004 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 93 Sayı: 3
  • Basım Tarihi: 2004
  • Doi Numarası: 10.1080/08035250310007475
  • Dergi Adı: ACTA PAEDIATRICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.361-367
  • Anahtar Kelimeler: bilirubin toxicity, brainstem auditory-evoked potentials, development, exchange transfusion, neonatal jaundice, NEONATAL HYPERBILIRUBINEMIA, BILIRUBIN, BRAIN, NEWBORN, GUIDELINES, JAUNDICE
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Aim: To evaluate prospectively non-haemolytic term infants with marked hyperbilirubinaemia treated by phototherapy only for evidence of bilirubin toxicity at 2 - 6 y of age, and to determine the suitability for Turkish children of the exchange transfusion limits recently reported by the American Academy of Pediatrics. Methods: The study group included a total of 30 children, aged 2 - 6 y, who had developed marked hyperbilirubinaemia (20 - 24 mg dl(-1), 342 - 410 mumol l(-1)) during the newborn period (gestational age >37 wk, birthweight >2500 g) and were treated without exchange transfusion because intensive phototherapy, instituted during the preparations for exchange transfusion, was successful in decreasing their serum bilirubin levels. The control group consisted of 30 children of the same age group without clinical jaundice in the newborn period. Physical and neurological examinations, brainstem auditory-evoked potentials (BAEPs) and developmental tests for Turkish children were performed in both the study and control children. Results: There was no difference between the groups with regard to mean BAEP latencies and developmental scores. None of the infants had hearing loss, developmental delay or abnormal neurological findings.